Ozempic mass tort case acquisition has emerged as one of the highest-volume plaintiff-firm investment decisions of 2026, driven by a documented claimant pool exceeding tens of millions of active GLP-1 users and a failure-to-warn theory strengthened by FDA labeling updates in 2023. The compensable injuries, gastroparesis, intestinal obstruction, aspiration pneumonia, and NAION-related vision loss, are serious and documentable. For firms allocating marketing budget, the core question is not whether this litigation is viable, but whether your acquisition economics can survive a competitive and still-consolidating docket.
The Business Case and the Risk: Why This Tort Demands Attention Now
The scale of GLP-1 prescribing is almost hard to wrap your head around. Novo Nordisk and Eli Lilly have two of the best-selling drug franchises in pharmaceutical history. That means the potential plaintiff population is not a few hundred thousand people, it is tens of millions of current and former users. Even injury rates that sound small in percentage terms translate into enormous absolute numbers. NAION, for instance, is estimated to affect roughly 1 in 10,000 semaglutide users. Do that math against a prescription base in the tens of millions and you are looking at a meaningful plaintiff population from that injury track alone, before you even count gastroparesis and obstruction cases.
The risk side of the business case is equally real. MDL 3094 in the Eastern District of Pennsylvania currently has more than 10,000 plaintiffs, but no bellwether trial dates are confirmed and no settlements are on the table. First verdicts are realistically 2026 at the earliest, possibly later. That means capital deployed today will be locked up for a while. Firms that went in early on other long-cycle MDLs know how that math works. You are making a portfolio bet, not a short-cycle flip.
The firms that will come out ahead are the ones that understand the economics clearly before they commit ad budget, not after.
Litigation Landscape: MDL Status, Bellwether Timeline, and What It Means for Case Value
MDL 3094 was centralized in late 2023 before Judge Gene Pratter in the Eastern District of Pennsylvania. The case load is growing fast, which is both a sign of the opportunity and a signal of how competitive signing cases is becoming. Discovery is ongoing. Science is still developing around the causal mechanisms, though the FDA label update for gastroparesis risk in 2023 gives plaintiffs a solid foundation for failure-to-warn arguments.
No bellwether trial schedule has been formally set as of this writing. The realistic window is 2025 for bellwether selection with trials running 2026 or later. That timeline has meaningful implications for how you value a signed case today. Early-stage MDL inventory bought at good cost-per-case numbers has historically been the best position to be in when settlements eventually materialize. The firms that wait for bellwether verdicts before committing ad dollars typically find that CPL has tripled and the best cases are already signed.
There are two defendants with deep pockets. Novo Nordisk is one of the most profitable pharmaceutical companies in the world. Eli Lilly is not far behind. Neither is going to fold quickly, but neither faces the kind of financial existential risk that makes defendants drag out litigation indefinitely. Global settlement is a realistic outcome once science and verdicts crystallize. The injury profiles, especially permanent gastroparesis and vision loss, are the kind of severe, documented harms that historically drive significant per-case values in pharmaceutical MDLs.
The Claimant Pool and Addressable Demand: Is There Still Volume to Capture?
Yes. The addressable pool here is genuinely large. GLP-1 prescriptions are nationwide, high-volume, and not concentrated in any particular region or demographic. Semaglutide and tirzepatide have been prescribed across all 50 states, in every age bracket over roughly 40, and across income levels given how aggressively insurers and manufacturers pushed access. That creates a geographically unconstrained acquisition environment, which is unusual in mass torts.
The qualifying population for the core injury tracks breaks down roughly like this from the firm's perspective. Gastroparesis and ileus cases need documented GI diagnosis following GLP-1 use, ideally with hospitalization records. Aspiration pneumonia cases often center on surgical settings where the patient's retained stomach contents led to a serious complication. NAION cases need ophthalmological documentation of sudden vision loss. Each track has its own evidentiary requirements, but all three have a large upstream pool of potential qualified claimants to draw from.
Saturation level at this moment is moderate. The MDL is growing fast, which means aggregators and national firms have been marketing for a year-plus. But this is not a tort where the best leads have already been picked clean. The sheer size of the GLP-1 user base means there is still meaningful unaddressed volume, particularly in the NAION track, which has received far less marketing attention than gastroparesis.
Ozempic Mass Tort Case Acquisition Economics: CPL, Cost-Per-Case, and Channel Mix
This is where firms need real numbers, not ranges so wide they are meaningless. For Ozempic mass tort case acquisition on Facebook and Instagram right now, qualified leads are running in the $150 to $350 range depending on injury track, creative quality, and targeting precision. Gastroparesis leads tend to be cheaper to generate because the condition is more widely discussed and easier for audiences to self-identify. NAION leads cost more to generate but often convert at higher rates because the injury is specific and severe.
Cost per signed case, assuming a competent intake operation, is currently running somewhere in the $1,200 to $2,800 range for firms with good creative and disciplined qualification. That range will compress as competition increases, so firms waiting six months to enter the market will pay more per case. That is the cycle in every mass tort, and Ozempic is not different.
Facebook and Instagram remain the highest-volume channels for this tort. The visual nature of the injury stories, particularly vision loss from NAION, lends itself to video creative. Short-form video ads explaining the drug connection to specific symptoms perform better than static image ads in most tests we have run. YouTube pre-roll is worth testing as a supplemental channel, especially for reaching an older demographic. Search intent is surprisingly modest for this tort relative to its size, which means paid search alone will not fill a pipeline.
Creative angles that convert: focus on the specific injury, not the drug name alone. Ads that lead with "stomach paralysis after taking diabetes or weight loss medication" or "sudden vision loss linked to GLP-1 drugs" outperform generic Ozempic lawsuit ads in most tests. The specificity helps with both click quality and downstream qualification rates.
Intake and Qualification: How to Run the Firm Side Cleanly
Qualification criteria matter enormously in a tort this young because the science is still developing and you do not want a docket full of marginal cases when bellwether selection arrives. The core intake questions for every track are: confirmed GLP-1 drug use (which drug, for how long), documented injury diagnosis from a treating provider, and a clear timeline connecting the two.
For gastroparesis cases, look for gastric emptying study results, hospitalization, or GI specialist diagnosis. For NAION, you need ophthalmology records documenting the vision event. Aspiration pneumonia cases should have hospital records showing the event occurred in a surgical context where the patient's GLP-1 use was a contributing factor.
Retainer flow should move fast. The firms burning money on leads and then letting them sit in an intake queue for 72 hours are the same firms complaining about high cost per case. Speed-to-contact and speed-to-retainer are the two operational levers that matter most. AI-assisted intake tools can compress both timelines significantly. Automated SMS follow-up, AI pre-screening questionnaires, and smart routing to human intake staff based on injury track are all being used by sophisticated firms right now. If your firm is not using any of these, the firms competing with you for the same leads probably are. That is a topic covered in depth in "A Lawyer's Guide to AI" if you want a practical framework for building that infrastructure.
How MTAA Runs Ozempic Campaigns
At Mass Tort Ad Agency, we have been managing Ozempic mass tort case acquisition campaigns since the MDL formed. Our model is transparent cost-plus: you see every dollar of ad spend, and we charge a 15% management fee on top of it. No markups, no hidden inventory margins. With $250M in managed Facebook spend across 600-plus plaintiff firms and 100-plus torts, we have the creative testing volume and audience data to move faster up the learning curve than a firm starting from scratch.
We handle full campaign management, creative development, audience segmentation, and lead delivery. For firms that also want help building out the intake side, we can connect you with AI-assisted intake tools that integrate with your case management system. The combination of optimized acquisition and fast intake is where the real efficiency gains are in a competitive MDL environment.
The Bottom Line on Ozempic Mass Tort Case Acquisition
The window to build an Ozempic docket at reasonable economics is open, but it is not unlimited. MDL 3094 is growing fast, defendants have resources, and the injury science is maturing in plaintiffs' favor. Ozempic mass tort case acquisition today means buying early-stage MDL inventory before bellwether verdicts push CPL higher and sign rates tighter. Firms that move now with a disciplined intake and qualification operation are positioned well. Firms that wait for more certainty will pay for that certainty at the acquisition level. That is the trade-off, and it is the same trade-off every serious mass tort presents.
If your firm wants to understand the real numbers before committing budget, that conversation starts with honest acquisition economics, not projections built on best-case assumptions. That is what we do at MTAA.
Ready to Build Your Caseload?
Get a free campaign analysis from Mass Tort Ad Agency.
$250M+ in mass tort Facebook ad spend. 600+ law firms served. Transparent cost-plus pricing with no hidden fees.
Schedule a Free Consultation →Frequently Asked Questions: Advertising Ozempic GLP-1 Cases
What is the estimated size of the qualifying claimant pool for Ozempic GLP-1 litigation, and is there enough volume to justify a dedicated acquisition budget?
With tens of millions of current and former semaglutide and tirzepatide users in the United States, the absolute claimant population is substantial even at low injury incidence rates. NAION alone is estimated to affect roughly 1 in 10,000 semaglutide users, which translates to thousands of potential plaintiffs from that single injury track before accounting for gastroparesis, intestinal obstruction, and aspiration pneumonia cases. For firms evaluating volume risk, the prescription base is large enough that claimant supply is not the primary constraint at this stage of the litigation cycle.
What are realistic cost-per-lead and cost-per-signed-case benchmarks for Ozempic mass tort acquisition in the current market?
Cost-per-signed-case figures for Ozempic cases have ranged widely depending on injury type, media channel, and how aggressively competing firms are bidding, but early movers have reported signed-case costs that remain competitive relative to projected case values for serious injury tracks like gastroparesis and NAION. Lead costs are highly sensitive to qualification criteria, since the broader GLP-1 user population requires tight intake filtering to isolate documented serious injuries from general side-effect complaints. Firms should model acquisition economics against conservative settlement projections rather than peak MDL comps to stress-test their intake ROI before committing significant budget.
Which advertising channels are most effective for acquiring qualified Ozempic plaintiff leads at scale for a plaintiff firm?
Television, connected TV, and programmatic video remain the highest-volume channels for mass tort claimant acquisition, but Ozempic campaigns benefit from layered digital targeting because the diagnosed injury conditions, particularly NAION and gastroparesis, allow for precise audience segmentation on social and search platforms. A cost-plus media model, where the firm owns the media buy and pays the vendor a transparent management fee rather than a per-lead markup, typically produces better economics at scale by eliminating the arbitrage margin built into traditional lead-generation pricing. Creative messaging for this tort should lead with the specific injury and the FDA labeling update rather than generic drug-injury framing to improve qualification rates at the top of the funnel.
How does the 2023 FDA labeling update strengthen the failure-to-warn theory, and why does it matter for case valuation at intake?
The FDA's 2023 requirement that Novo Nordisk update Ozempic and Wegovy labeling to include gastroparesis-related warnings created a documented regulatory acknowledgment that the risk was underreported to prescribers and patients prior to that date, which is a foundational element of a viable failure-to-warn claim. Cases with injury onset or diagnosis before the labeling change are generally stronger on the notice theory because they fall within the window when the manufacturer had or should have had the information but failed to act. Firms should use the labeling timeline as a primary intake filter to prioritize pre-2023 injury cases and tier their acquisition spend accordingly.
How saturated is the Ozempic mass tort advertising market right now, and is there still a first-mover advantage available to firms entering in the current cycle?
The Ozempic tort has attracted significant attention from the plaintiff bar, but advertising saturation is meaningfully lower than established MDLs like talc or NEC formula litigation because many firms are still in the evaluation phase rather than active acquisition mode. Firms that commit to paid media now are competing against a smaller pool of active advertisers than they will face if the tort consolidates into a formal MDL and national brands flood the market. The strategic window for building an inventory of signed cases at pre-saturation acquisition costs is real but finite, making timing of budget commitment a material business decision rather than a speculative one.
